Keeps LegitScript and Accreditation Status: Is Keeps a Legitimate Telehealth Provider?

What Is LegitScript Certification and Does Keeps Have It?

LegitScript is the third-party verification service that Google, Meta, and major payment processors use to approve online pharmacy advertising. Earning certification requires a pharmacy or telehealth platform to pass a documented review of licensing, prescription practices, drug sourcing, and privacy policy compliance.

Keeps has passed that review. As of the most recent public database check, Keeps appears in LegitScript's directory under the "Legitimate Online Pharmacy" classification, meaning it met the organization's requirements for lawful dispensing at the time of certification. LegitScript re-audits certified entities on a rolling basis, so status can change if a platform falls out of compliance.

What LegitScript Actually Checks

LegitScript's certification process examines four core areas: (1) whether the site requires a valid prescription from a licensed practitioner, (2) whether dispensing pharmacies hold active state licenses, (3) whether the drugs sold are approved or otherwise legally marketed in the jurisdiction, and (4) whether the site's privacy and payment practices comply with applicable law.

Keeps requires an asynchronous clinical intake before issuing any prescription. A licensed physician reviews the patient's photos and health history, then issues a prescription only if clinically appropriate. That workflow satisfies LegitScript's prescription requirement.

Why LegitScript Status Matters for Patients

Unverified online pharmacies are responsible for a large share of counterfeit and adulterated drugs entering the U.S. Market. The FDA's BeSafeRx campaign specifically directs patients to look for LegitScript or NABP (.pharmacy domain) verification before purchasing prescription drugs online. LegitScript certification is not a government license, but it does signal that an independent auditor has reviewed the platform's practices against a defined legal standard.

Are the Drugs Keeps Sells FDA-Approved?

Yes. Keeps sells finasteride 1 mg tablets and topical minoxidil, both of which carry FDA approval for male-pattern hair loss. That is the starting point for any legitimacy assessment of a hair-loss platform.

Finasteride 1 mg (Propecia)

The FDA approved finasteride 1 mg (brand name Propecia, Merck) for androgenetic alopecia in men in December 1997. The approval was based on five randomized controlled trials involving 1,879 men aged 18 to 41 with mild-to-moderate vertex and anterior mid-scalp hair loss. At 12 months, 83% of finasteride-treated men maintained or increased hair count versus 28% on placebo [1].

A 5-year extension study showed continued efficacy: mean hair count increased by 277 hairs per 1-inch circle versus a decrease of 138 hairs in placebo-treated men at year 5 [2]. Keeps dispenses generic finasteride 1 mg, which is bioequivalent to Propecia under FDA's abbreviated new drug application (ANDA) pathway.

The FDA label carries a Boxed Warning that finasteride must not be handled by women who are pregnant or who may become pregnant due to risk of fetal harm, and it includes post-marketing reports of persistent sexual side effects after discontinuation. Keeps' intake form asks about sexual health history, which is the appropriate clinical screen before prescribing.

Minoxidil (Rogaine and Generics)

Topical minoxidil 5% solution was FDA-approved for men in 1991; the 5% foam formulation received approval in 2006. A 48-week double-blind trial (N=352) showed that men using 5% minoxidil solution had 45% more hair regrowth than men using 2% minoxidil [3]. Keeps offers both concentrations, which aligns with FDA-approved dosing options.

Oral minoxidil is used off-label at low doses (0.625 mg to 2.5 mg daily) for hair loss. As of this article's review date, Keeps' primary product offering centers on topical minoxidil, though the platform's formulary has expanded over time.

Keeps' Pharmacy Network and State Licensing

Keeps is not itself a pharmacy. It operates as a telehealth platform that connects patients to physicians and routes approved prescriptions to third-party dispensing pharmacies. The legitimacy of that chain depends on whether the fulfillment pharmacies hold active state licenses and whether they are enrolled in recognized accreditation programs.

NABP Enrollment

The National Association of Boards of Pharmacy (NABP) maintains a .pharmacy accreditation program separate from LegitScript. Pharmacies in Keeps' network are represented as state-licensed. Patients can independently verify any dispensing pharmacy's license through their state pharmacy board's public lookup tool, which is the most direct verification method available.

Prescription Issuance and the Ryan Haight Act

Federal law under the Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. 829) generally requires that a controlled substance prescription issued via telemedicine be preceded by at least one in-person medical evaluation. Finasteride and minoxidil are not controlled substances, so they fall outside that specific requirement. They are, however, still prescription drugs (finasteride) or OTC drugs (topical minoxidil), and prescribing finasteride without any physician-patient interaction would violate state medical practice acts.

Keeps' asynchronous model, in which a licensed physician reviews a patient's photos and questionnaire before prescribing, has been accepted by multiple state medical boards as a valid form of telemedicine encounter for non-controlled prescription drugs. Requirements differ by state, and Keeps' own terms note that service may not be available in every jurisdiction.

BBB Profile: Rating, Accreditation, and Complaints

The Better Business Bureau is not a government regulator, but its complaint database provides a structured, publicly accessible record of consumer disputes and company responses. For telehealth platforms, the BBB file gives insight into billing, shipping, and customer-service patterns.

Current BBB Status

Keeps holds BBB accreditation. BBB accreditation requires a business to meet standards for transparency, advertising accuracy, responsiveness to complaints, and business practices. The company has responded to complaints filed on the BBB platform, which is a basic threshold BBB tracks.

Nature of Logged Complaints

Reviewing the BBB complaint categories for Keeps, the most frequently logged issues fall into three areas: subscription cancellation difficulty, unexpected charges after attempted cancellation, and shipping delays. These are common patterns for D2C subscription businesses broadly, and they are not specific to drug safety or prescribing legitimacy.

Fewer complaints involve the clinical side of the service, such as prescription errors or drug quality issues. That distribution is meaningful: it suggests the platform's primary friction points are administrative rather than medical.

The FDA's MedWatch system is the appropriate channel for reporting adverse drug events, not the BBB. Patients who experience side effects from finasteride or minoxidil obtained through Keeps should report those events via FDA MedWatch at fda.gov/safety/medwatch [4].

How to Read Complaint Volume in Context

Keeps has served a large patient volume since 2018. A raw complaint count without a denominator (total patients served) does not indicate a high complaint rate. Context matters. A platform with 500,000 active subscribers and 200 BBB complaints has a complaint rate below 0.05%, which is lower than the industry median for subscription health services.

Clinical Evidence Underlying Keeps' Treatments

A platform can hold every certification available and still prescribe treatments with weak evidence. Keeps' two core offerings have some of the strongest long-term evidence in dermatology.

Finasteride: The 5-Year PLESS Data

The Proscar Long-Term Efficacy and Safety Study (PLESS) was a 4-year randomized controlled trial of finasteride 5 mg in 3,040 men. While PLESS used the 5 mg BPH dose rather than the 1 mg hair-loss dose, the same 5-alpha reductase inhibition mechanism applies. Data from the 1 mg program showed statistically significant hair count increases versus placebo at every annual time point through year 5 [2]. The FDA reviewed these data as part of the Propecia NDA and cited the 5-year program as the basis for its long-term efficacy claims.

The American Academy of Dermatology (AAD) guidelines on androgenetic alopecia state that finasteride 1 mg daily is a Level A recommendation for men, meaning supported by at least two well-designed randomized controlled trials [5].

Minoxidil: Mechanism and Trial Data

Minoxidil prolongs the anagen (growth) phase of the hair cycle and may increase follicular size. The 48-week key trial supporting the 5% foam FDA approval (N=352 men, randomized, double-blind, vehicle-controlled) showed a mean increase of 12.4 hairs per cm2 in the 5% group versus vehicle [3].

For patients who do not respond to monotherapy, combining finasteride and minoxidil produces additive benefit. A 2021 randomized trial (N=450) published in the Journal of the American Academy of Dermatology found that combination therapy produced significantly greater hair count improvement at 12 months than either agent alone (P<0.001) [6]. Keeps offers both drugs, which allows patients to access this combination if their physician determines it appropriate.

How Keeps Compares to Other Accredited Hair-Loss Platforms

Keeps operates in a competitive space alongside Hims, Roman, and Numan, among others. All of these platforms use a similar D2C telemedicine model and sell finasteride and minoxidil.

Regulatory Parity

Hims holds LegitScript certification. Roman (now part of Ro) holds LegitScript certification. The presence of LegitScript certification across multiple competitors does not make it meaningless. It does mean that LegitScript status alone is not a differentiator. Patients should evaluate platforms on physician availability, formulary breadth, price transparency, and cancellation policies.

Price and Formulary Differences

Keeps' generic finasteride pricing has historically been competitive, ranging from approximately $20 to $35 per month depending on subscription length, compared to retail pharmacy prices of $30 to $80 per month for the same generic without insurance. Minoxidil 5% foam is similarly priced near or below major retail pharmacy pricing.

The HealthRX editorial team developed the following decision framework for evaluating any D2C hair-loss platform on legitimacy criteria.

HealthRX Platform Legitimacy Checklist:

1. LegitScript or NABP .pharmacy certification: present or absent.
2. Drugs sold are FDA-approved or clearly disclosed as off-label with evidence citation.
3. Prescriptions issued only after physician review (sync or async).
4. Dispensing pharmacy holds active state license verifiable via public board lookup.
5. Adverse event reporting pathway disclosed (MedWatch link or equivalent).
6. Cancellation policy is written, accessible before purchase, and honored in complaint responses.
7. Pricing disclosed before checkout, with no hidden auto-enrollment in higher tiers.

Keeps satisfies items 1 through 5 based on available public information. Items 6 and 7 are the source of the most BBB complaints, suggesting the company's clinical infrastructure is stronger than its billing and cancellation practices.

What Patients Should Verify Before Starting Keeps

Checking a platform's certifications is a starting point. Patients should also take several independent steps before subscribing to any telehealth hair-loss service.

Confirm Your State's Availability

Telehealth prescribing rules vary by state. Some states require synchronous (live video) encounters for new prescriptions. Keeps' service area does not cover all 50 states for all products. The company's onboarding flow will indicate whether service is available in your state, but checking before entering payment information saves time.

Review the FDA Label for Finasteride

The finasteride 1 mg FDA label is publicly available on FDA's DailyMed database [1]. The label includes the complete list of adverse reactions, including decreased libido (1.8% vs. 1.3% placebo), erectile dysfunction (1.3% vs. 0.7% placebo), and ejaculation disorder (1.2% vs. 0.7% placebo) from the key trials. A physician should review these with you before prescribing. Keeps' intake questionnaire covers sexual health history, but patients should not rely solely on a questionnaire for informed consent on a prescription drug.

Understand the Subscription Terms

The BBB complaint record for Keeps includes repeated accounts of charges continuing after patients believed they had cancelled. Before subscribing, locate the cancellation policy in writing, note the required cancellation window before the next billing date, and save documentation of any cancellation request.

Report Side Effects Through Official Channels

If you experience a suspected adverse reaction to finasteride or minoxidil dispensed by Keeps, file a report with FDA MedWatch (fda.gov/safety/medwatch) [4]. This creates a formal record, contributes to post-marketing safety surveillance, and is more consequential than a BBB complaint for drug safety purposes.

Regulatory and Legal Considerations

Keeps, like all D2C telehealth platforms, operates under a layered regulatory structure. Understanding which agency governs which aspect helps patients know where to escalate concerns.

FDA

The FDA regulates the drugs themselves. If Keeps were to sell unapproved drugs, adulterated formulations, or misbranded products, the FDA would be the enforcement agency. As of this writing, Keeps has not been the subject of an FDA warning letter. The FDA's warning letter database is publicly searchable at fda.gov [4].

State Medical Boards

Physicians who prescribe through Keeps are licensed by the medical board of the state in which the patient resides. If a prescribing physician acts outside the standard of care, the relevant state medical board is the appropriate reporting body. Complaints about prescribing practices should go to the state board, not the BBB.

State Pharmacy Boards

The pharmacy dispensing Keeps' prescriptions is licensed by a state pharmacy board. Dispensing errors, drug quality issues, or licensing violations fall under state pharmacy board jurisdiction. NABP maintains a directory of state board contact information.

FTC

The Federal Trade Commission has authority over deceptive advertising claims. If Keeps made clinically unsupported efficacy claims for its products, the FTC would be the relevant agency. The AAD's Level A evidence for finasteride means that standard efficacy claims ("helps stop hair loss," "promotes regrowth") are supportable. Claims about unapproved uses or exaggerated outcomes would be a different matter.